Publications

Our company’s R&D activities are focusing on discovery and clinical applications of molecular targeted radiotherapy. Below you can find a selection of recent publications co-authored by 3BP’s staff.

  1. Zboralski D, Osterkamp F, Christensen E, Bredenbeck A, Schumann A, Hoehne A, Schneider E, Paschke M, Ungewiss J, Haase C, Robillard L, Simmons AD, Harding TC, Nguyen M. Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition. Eur J Nucl Med Mol Imaging. 2023 Apr 22. doi: 10.1007/s00259-023-06211-6. PMID: 37086273.
  2. Dirk Zboralski, Aileen Höhne, Esben Christensen, Matthias Paschke, Liliane Robillard, Andrew D. Simmons, Frank Osterkamp, Thomas C. Harding, Minh Nguyen. Fibroblast activation protein (FAP)-targeted radiotherapy increases tumor CD8+ T cell infiltration and enhances response to PD-1 immune checkpoint blockade [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2835.
  3. Zboralski D, Hoehne A, Bredenbeck A, Schumann A, Nguyen M, Schneider E, Ungewiss J, Paschke M, Haase C, von Hacht JL, Kwan T, Lin KK, Lenore J, Harding TC, Xiao J, Simmons AD, Mohan AM, Beindorff N, Reineke U, Smerling C, Osterkamp F. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3651-3667. doi: 10.1007/s00259-022-05842-5. Epub 2022 May 24. PMID: 35608703.
  4. Jonathan McConathy, Mallika Dhawan, Ajit H. Goenka, Emerson A. Lim, Yusuf Menda, Beth Chasen, Moh’d Khushman, Akiva Mintz, Yousef Zakharia, John J. Sunderland, Owen Bowles, Jim Xiao, Andrew D. Simmons, Kenton Wride, Aaron Enke, Thomas A. Hope. LuMIERE: A phase 1/2 study investigating safety, pharmacokinetics, dosimetry, and preliminary antitumor activity of 177Lu-FAP-2286 in patients with advanced or metastatic solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT251.
  5. Dirk Zboralski, Aileen Hoehne, Anne Bredenbeck, Matthias Paschke, Jan Lennart von Hacht, Jim Xiao, Andrew D. Simmons, Frank Osterkamp, Thomas Harding, Minh Nguyen. Comparative biodistribution and radiotherapeutic efficacy of the fibroblast activation protein (FAP)-targeting agents FAP-2286 and FAPI-46 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3317.
  6. Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, Zhang J, Mueller D, Eismant A, Almaguel F, Zboralski D, Osterkamp F, Hoehne A, Reineke U, Smerling C, Kulkarni HR. Feasibility, Biodistribution and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy (PTRT) of Diverse Adenocarcinomas using 177Lu-FAP-2286: First-in-Human Results. J Nucl Med. 2021 Jun 24:jnumed.120.259192. doi: 10.2967/jnumed.120.259192. Epub ahead of print. PMID: 34168013.
  7. Rottenburger C, Nicolas GP, McDougall L, Kaul F, Cachovan M, Vija AH, Schibli R, Geistlich S, Schumann A, Rau T, Glatz K, Behe M, Christ ER, Wild D. Cholecystokinin-2 Receptor Agonist 177-Lutetium-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma – Results of the Lumed Phase 0a Study. J Nucl Med. 2019 Sep 13. pii: jnumed.119.233031. doi: 10.2967/jnumed.119.233031. [Epub ahead of print] PubMed PMID: 31519804.
  8. Zboralski D, Frömming A. Generation and Harnessing of Heterotypic Tumor-Stroma Spheroids to Study Cancer Immunosurveillance. Methods Mol Biol. 2019;1884:269-281. doi: 10.1007/978-1-4939-8885-3_19. PubMed PMID: 30465210.
  9. Baum RP, Singh A, Schuchardt C, Kulkarni HR, Klette I, Wiessalla S, Osterkamp F, Reineke U, Smerling C. 177-Lutetium-3BP-227 for Neurotensin Receptor 1-Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results. J Nucl Med. 2018 May;59(5):809-814. doi: 10.2967/jnumed.117.193847. Epub 2017 Oct 12. PubMed PMID: 29025990
  10. Schulz J, Rohracker M, Stiebler M, Goldschmidt J, Stöber F, Noriega M, Pethe A, Lukas M, Osterkamp F, Reineke U, Höhne A, Smerling C, Amthauer H. Proof of Therapeutic Efficacy of a 177-Lutetium-Labeled Neurotensin Receptor 1 Antagonist in a Colon Carcinoma Xenograft Model. J Nucl Med. 2017 Jun;58(6):936-941. doi: 10.2967/jnumed.116.185140. Epub 2017 Mar 2. PubMed PMID: 28254866.
  11. Schulz J, Rohracker M, Stiebler M, Goldschmidt J, Grosser OS, Osterkamp F, Pethe A, Reineke U, Smerling C, Amthauer H. Comparative Evaluation of the Biodistribution Profiles of a Series of Nonpeptidic Neurotensin Receptor-1 Antagonists Reveals a Promising Candidate for Theranostic Applications. J Nucl Med. 2016 Jul;57(7):1120-3. doi: 10.2967/jnumed.115.170530. Epub 2016 Mar 3. PubMed PMID: 26940767.
  12. Gourni E, Mansi R, Jamous M, Waser B, Smerling C, Burian A, Buchegger F, Reubi JC, Maecke HR. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68-Gallium – and 64-Copper-labeled peptides for PET imaging. J Nucl Med. 2014 Oct;55(10):1719-25. doi: 10.2967/jnumed.114.141242. Epub 2014 Aug 21. PubMed PMID: 25146125.